Misawa Tamako, Mizusawa Hidehiro
Department of Neurology and Neurological Science, Tokyo Medical and Dental University.
Nihon Rinsho. 2008 Jun;66(6):1135-9.
Multiple sclerosis (MS) is considered as an autoimmune disease targeted to myelin and oligodendrocytes, which leads to inflammatory demyelination in the central nervous system (CNS). MS is possibly a polygenetic and multifactorial disorder in which the interaction between various genetic and environmental factors could cause clinically and pathologically heterogeneous phenotypes. Most of the previous efforts to predict clinical courses, therapeutic responses, and prognosis of MS have been unsuccessful. However, pharma-cogenomic approach by using DNA microarray, protein chip, genome-wide analysis of single nucleotide polymorphism, and bioinformatics technology has been recently established. It would help us to understand the disease mechanisms, and to identify diagnostic markers and novel therapeutic targets, and to precisely predict therapeutic responses and adverse events. This comprehensive approach promotes the development of tailored therapy in MS as well as in other neurological disorders of complex etiology.
多发性硬化症（MS）被认为是一种针对髓鞘和少突胶质细胞的自身免疫性疾病，可导致中枢神经系统（CNS）发生炎性脱髓鞘。MS可能是一种多基因和多因素疾病，其中各种遗传和环境因素之间的相互作用可导致临床和病理上的异质性表型。此前大多数预测MS临床病程、治疗反应和预后的努力均未成功。然而，最近已建立了通过使用DNA微阵列、蛋白质芯片、全基因组单核苷酸多态性分析和生物信息学技术的药物基因组学方法。这将有助于我们了解疾病机制，识别诊断标志物和新的治疗靶点，并精确预测治疗反应和不良事件。这种综合方法促进了MS以及其他病因复杂的神经系统疾病的个体化治疗的发展。
